Bcl-6 inhibitor (Kd = 3 μM); exhibits 10-fold greater potency than endogenous Bcl-6 corepressors. Disrupts formation of Bcl-6 repression complex. Induces regression of established tumors in mice bearing DLBCL xenograft.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 368.82. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.71 mL||13.56 mL||27.11 mL|
|5 mM||0.54 mL||2.71 mL||5.42 mL|
|10 mM||0.27 mL||1.36 mL||2.71 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the biological activity of the product.
Cardenas et al (2016) Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J.Clin.Invest. 126 3351 PMID: 27482887
Cardenas et al (2017) The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. Clin.Cancer Res. 23 885 PMID: 27881582
If you know of a relevant reference for FX 1, please let us know.
View Related Products by Product Action
Keywords: FX 1, FX 1 supplier, FX1, Bcl, family, BCL6, inhibitors, inhibits, B, cell, lymphoma, 6, Diffuse, large, lymphomas, DLBCLs, Cell, CLL, Lymphoma, Bcl-2, Family, 6323, Tocris Bioscience
Citations for FX 1
Citations are publications that use Tocris products.
Currently there are no citations for FX 1. Do you know of a great paper that uses FX 1 from Tocris? Please let us know.
Reviews for FX 1
There are currently no reviews for this product. Be the first to review FX 1 and earn rewards!
Have you used FX 1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.